ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

With popular asthma inhaler now discontinued, what other options do patients have?

Glaxo Smith Kline (GSK) announced in May that Flovent HFA, a metered-dose inhaler, as well as Flovent Diskus, a dry powder inhaler, would be discontinued as of Dec. 31, 2023. Experts weigh in.

Flovent, a popular corticosteroid inhaler used to treat asthma, is no longer available.

The global manufacturer, Glaxo Smith Kline (GSK), announced in May that the medications — Flovent HFA, a metered-dose inhaler, as well as Flovent Diskus, a dry powder inhaler — would be discontinued as of Dec. 31, 2023.

It is expected that the existing supply of Flovent products will be exhausted by early 2024, the company said in the statement, which was also provided to Fox News Digital on Tuesday.

PFIZER SCRAPS TWICE-DAILY WEIGHT LOSS PILL DANUGLIPRON AFTER STUDY SHOWS ‘HIGH RATES’ OF ADVERSE SIDE EFFECTS

In an effort to meet patients’ needs, GSK has launched generic versions of both products.

"As part of our commitment to be ambitious for patients, we launched an authorized generic for Flovent HFA (fluticasone propionate inhalation aerosol) in May 2022 and intend to launch an authorized generic for Flovent Diskus (fluticasone propionate inhalation powder) in October 2023" as "potentially lower cost alternatives," the company said in a statement sent to the Asthma and Allergy Foundation of America (AAFA) in November 2023.

The company said it expects "minimal disruption for patients" in the transition from the branded medications to the authorized generics.

The generics will be manufactured by GSK and distributed by Prasco LLC.

NARCAN NASAL SPRAY IS AVAILABLE FOR OVER-THE-COUNTER PURCHASE IN US: ‘LIFESAVING DRUG’

Dr. Purvi Parikh, an allergist and immunologist with Allergy & Asthma Network in New York, expects there to be at least some amount of disruption.

"I think it will disrupt treatment for some patients while they scramble to find an alternative covered by their insurance," she told Fox News Digital, sharing her opinion.

Melanie Carver, chief mission officer of AAFA, noted that the U.S. has a "complicated drug pricing ecosystem."

DELTA AIR LINES BACKS FLIGHT ATTENDANT WHO DENIED PASSENGER’S ALLERGY ACCOMMODATION

"Manufacturers, pharmacy benefit managers, insurance companies and federal policies can create situations that reduce access to critical medications for patients," Carver told Fox News Digital.

In addition to GSK’s generic offerings, there is also a generic metered dose inhaler made by RPK Pharmaceuticals that has the same dosing, said Parikh.

"The efficacy will be the same [for] all of these," she said. 

For people who are currently taking Flovent, Parikh recommends speaking with a doctor about switching.

"The generics aren’t as widely covered or they may require prior authorization, so [some patients] may have to change to a different brand altogether," she added.

Access to the authorized generic fluticasone will depend on people's health insurance and their pharmacy benefits, Carver pointed out.

"While we hope that most plans will replace the brand name Flovent with the authorized generic, there may be some that don’t, and that will create challenges for patients to get the medicine they need," she told Fox News Digital.

For those who are currently using brand name Flovent HFA or Flovent Diskus, Carver recommends checking with insurance providers to see if the authorized generic versions are covered. 

"For some people, the out-of-pocket costs may unexpectedly be higher with the generic if their plan doesn’t have the authorized generics on their preferred drug lists," she warned.

It’s important that people who have asthma continue to take their medications, Carver said — particularly during the winter season, when respiratory illnesses typically spike.

"Fluticasone works by controlling inflammation and swelling in the airways to prevent asthma attacks," she said. 

"Pharmacy delays can put a person with asthma at risk of worsening inflammation."

PATIENTS STOP WEGOVY, OTHER WEIGHT LOSS-RELATED DRUGS SHORTLY AFTER STARTING, DOCTORS SAY

For patients whose insurance plans will not cover the authorized generic medication, there are other inhaler options, including ArmonAir Digihaler and Arnuity Ellipta. 

"ArmonAir Digihaler is an alternative for Flovent Diskus. The formulation is the same but slightly different doses are available," said Carver.

"Arnuity Ellipta is an inhaled steroid but not a direct substitute for Flovent HFA or Flovent Diskus."

Patients should check with their doctor to determine the appropriate dosage and the proper way to use the inhalers, Carver said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"Not all inhalers are used the same way," she said. 

"Some insurers are transitioning to breath-actuated inhalers (like the Diskus versions) on their preferred drug lists, but these are not appropriate for all patients."

GET FOX BUSINESS ON THE GO BY CLICKING HERE

When people are not trained on how to use their inhalers, this can lead to uncontrolled asthma and emergency room visits, Carver warned.

For more Health articles, visit www.foxbusiness.com/category/fox-news-health.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.